Marinus Pharmaceuticals (NASDAQ:MRNS) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Friday morning, Benzinga reports.

A number of other research analysts have also recently weighed in on the stock. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday. Royal Bank of Canada reduced their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, September 23rd. Finally, JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.07.

Marinus Pharmaceuticals Stock Up 36.9 %

Shares of MRNS stock opened at $0.41 on Friday. The stock has a market cap of $22.31 million, a price-to-earnings ratio of -0.15 and a beta of 1.14. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The firm’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.61.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period last year, the firm earned ($0.61) earnings per share. On average, equities analysts forecast that Marinus Pharmaceuticals will post -1.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $34,000. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $64,000. Finally, Values First Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.